Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arcoma ABOSTO:ARCOMA -0.25%75 EBIT per Share is kr0.34 as of Mar. 2026. GuruFocus rates OSTO:ARCOMA with a GF Score™ of 75/100 and a GF Value™ of kr7.87 (Fairly Valued). The stock has 1 warning sign investors should review. Among 688 Medical Devices & Instruments companies, Arcoma AB ranks better than 67.01% on this metric.
Arcoma AB's EBIT per Share for the
three
months ended in Mar. 2026 was kr0.07.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.34.
During the past 12 months, the average EBIT per Share Growth Rate of Arcoma AB was -64.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 22.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Arcoma AB's EBIT per Share or its related term are showing as below:
OSTO:ARCOMA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -339.9 Med: -30.9 Max: 63.1
Current: 22.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Arcoma AB was 63.10% per year. The lowest was -339.90% per year. And the median was -30.90% per year.
OSTO:ARCOMA's 3-Year EBIT Growth Rate is ranked better than 67.01% of 688
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs OSTO:ARCOMA: 22.50
Arcoma AB's EBIT for the
three
months ended in Mar. 2026 was kr1.0 Mil.
Arcoma AB (OSTO:ARCOMA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Arcoma AB EBIT per Share Related Terms
Arcoma AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Arcoma AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.34
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcoma AB (OSTO:ARCOMA) has a EBIT per Share of kr0.34 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Arcoma AB and its competitors. According to the industry distribution chart, Arcoma AB ranks #227 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 33%.
Is Arcoma AB's EBIT per Share too high?
Arcoma AB's current EBIT per Share is kr0.34. Based on the distribution chart, Arcoma AB ranks #227 out of 688 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Arcoma AB has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arcoma AB's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Arcoma AB ranks #227 out of 688 companies for EBIT per Share. This puts Arcoma AB in the upper half of its industry. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Arcoma AB and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcoma AB's current EBIT per Share is kr0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcoma AB stock overvalued right now?
Based on GuruFocus' analysis, Arcoma AB (OSTO:ARCOMA) is currently considered Fairly Valued. The stock's GF Value™ is kr7.87, compared to a current price of kr8.04 — trading 2.2% above its estimated fair value. The current EBIT per Share is kr0.34. Arcoma AB's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Arcoma AB (OSTO:ARCOMA), the current EBIT per Share is kr0.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcoma AB (OSTO:ARCOMA) Overvalued in 2026?
Based on GuruFocus' analysis, Arcoma AB stock appears to be overvalued.
The current stock price of kr8.04 is trading 2.2% above its estimated GF Value™ of kr7.87.
GuruFocus considers Arcoma AB to be Fairly Valued.
Key valuation signals for OSTO:ARCOMA:
EBIT per Share: kr0.34
GF Value™: kr7.87 vs. price of kr8.04 (2.2% above fair value)
No single metric tells the full story. See the OSTO:ARCOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcoma AB provides digital radiography systems in Sweden. It offers products including wireless flat panel detectors, positioning devices, and precision dr systems.
75GF Score
Get the complete analysis for OSTO:ARCOMA
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ARCOMA has been successfully added to your 
